Long intergenic non-protein coding RNA 1013 (LINC01013)

Long intergenic non-protein coding RNA 1013 (LINC01013) is a long non-coding RNA (lncRNA) gene that does not code for a classical protein but functions in the regulation of gene expression and epigenetic control. It is expressed in various tissues, including endothelium and fibroblasts, and has been associated with cancer progression, especially promoting invasion in anaplastic large-cell lymphoma by activating the Snail-fibronectin pathway, which is integral to epithelial-to-mesenchymal transition (EMT)[1]. LINC01013 is upregulated in response to TGFβ1 signaling in cardiac fibroblasts, where it can encode a previously unreported micropeptide from an internal small open reading frame (smORF) that itself can activate fibroblasts[4][6][7]. In calcific aortic valve disease (CAVD), LINC01013 is strongly upregulated and acts as a decoy for the negative transcription elongation factor E (NELF-E), facilitating increased transcription of the CCN2 gene, which is involved in fibrosis and remodeling[2][5]. It can act both in the nucleus and cytosol, modulating chromatin state and RNA polymerase activity, linking it to both transcriptional regulation and chromatin modification. To date, LINC01013 is not considered a classical drug target such as a receptor, enzyme, or transporter, and no drugs are known to directly interact with it. It is, however, a subject of biomarker research in oncology and cardiovascular pathology, and the micropeptide it encodes may represent a future therapeutic target or tool[4]. There are no current safety concerns reported, but therapeutic targeting of lncRNAs may require careful development to avoid off-target effects.

Other names

AERRIELINC01013ORFAge and EndMT Regulated RNA In EndotheliumLINC02921long intergenic non-protein coding RNA 2921